<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7290441\results\search\disease\results.xml">
  <result pre="receptor agonist, nylidrin, was identified as an antiviral compound against" exact="influenza" post="A virus. The molecule was effective against multiple isolates"/>
  <result pre="acidic pH. In a mouse model, preincubation of a mouse-adapted" exact="influenza" post="A virus (H1N1) with nylidrin completely blocked intranasal viral"/>
  <result pre="chemical skeleton for the development of a direct-acting inhibitor of" exact="influenza" post="A virus entry. influenza A virus hemagglutinin 2 fusion"/>
  <result pre="development of a direct-acting inhibitor of influenza A virus entry." exact="influenza" post="A virus hemagglutinin 2 fusion inhibitor nylidrin β2-adrenergic receptor"/>
  <result pre="mRNA synthesis. Despite the high potency of these drugs against" exact="influenza" post="A and/or B viruses, the emergence or global spread"/>
  <result pre="diacetate (FDA); hit compounds were those that allowed 80% of" exact="influenza" post="A or B virus-infected cells to survive at a"/>
  <result pre="[16,17]. One of the hits, nylidrin showed antiviral activity against" exact="influenza" post="A viruses, but not against influenza B viruses (Table"/>
  <result pre="showed antiviral activity against influenza A viruses, but not against" exact="influenza" post="B viruses (Table 1). Also known as buphenine, nylidrin"/>
  <result pre="analogues, ifenprodil and clenbuterol, reliably inhibited H1N1 isolates of the" exact="influenza" post="A virus. In the present study, we suggest that"/>
  <result pre="of HA that occur at low pH. Accordingly, preincubation of" exact="influenza" post="virus with nylidrin completely blocked intranasal infection of mice."/>
  <result pre="could lead to the development of a direct-acting antiviral against" exact="influenza" post="A with a distinct and novel mode of action."/>
  <result pre="grown overnight. The cells were mock-infected or infected with individual" exact="influenza" post="strains at a multiplicity of infection (MOI) of 0.001"/>
  <result pre="secondary antibody (Invitrogen). 2.7. Polykaryon Assay Syncytia formation caused by" exact="influenza" post="infection was evaluated as described previously [16,22]. Vero E6"/>
  <result pre="visualization of cell–cell fusion. Herein, a well-known neutralizing antibody for" exact="influenza" post="A virus HA2, MEDI8852, was chosen as a control"/>
  <result pre="[16,17], we identified nylidrin as a hit compound that inhibits" exact="influenza" post="A viruses (PR8 and HK). At a concentration of"/>
  <result pre="µM, nylidrin maintained 80% viability in MDCK cells infected with" exact="influenza" post="A, but conferred no benefit in CPE-reduction following infection"/>
  <result pre="but conferred no benefit in CPE-reduction following infection with an" exact="influenza" post="B strain (Lee). To verify this finding, we performed"/>
  <result pre="partially including nylidrin, ifenprodil, labetalol, eliprodil, and clenbuterol, against additional" exact="influenza" post="A and B viruses (Table 2). Nylidrin, ifenprodil, and"/>
  <result pre="the H3N2 viral strains, and none had antiviral activity in" exact="influenza" post="B-infected cells. As expected, the remaining two compounds, labetalol"/>
  <result pre="can reliably inhibit the infection of H1N1 strains of the" exact="influenza" post="A virus at subtoxic concentrations. 3.2. Field-Based Pharmacophore Analysis"/>
  <result pre="assay, it was necessary to determine whether nylidrin could inhibit" exact="influenza" post="viral infection by monitoring viral proteins or plaque reduction"/>
  <result pre="of viral entry. This time-of-addition experiment revealed that nylidrin affected" exact="influenza" post="virus replication in an incubation period-dependent manner (Figure 2C)."/>
  <result pre="infection in vivo by directly targeting the HA2 function of" exact="influenza" post="A virus (H1N1). 4. Discussion From screening of a"/>
  <result pre="identified nylidrin, an ADRB2 agonist, as an antiviral compound against" exact="influenza" post="A virus. ADRB2 is a G protein-coupled receptor (GPCR)"/>
  <result pre="an agonist of the �?�2 adrenergic receptor (ARDA2), inhibited various" exact="influenza" post="strains at the viral assembly step [29]. As a"/>
  <result pre="was wondered how ADRB2 agonists have antiviral activity against the" exact="influenza" post="A virus. Here, this question was answered by the"/>
  <result pre="point to be stressed is that nylidrin completely blocked intranasal" exact="influenza" post="infections of mice when it was preincubated with the"/>
  <result pre="suggest that although nylidrin is a potent, direct-acting inhibitor of" exact="influenza" post="virus HA2, the pharmacokinetics of gastrointestinal absorption is not"/>
  <result pre="gastrointestinal absorption is not sufficient for oral administration to treat" exact="influenza" post="virus infection. Future studies could also focus on chemical"/>
  <result pre="No effect of nylidin on the proton channel activity of" exact="influenza" post="viral M2, Figure S4: Increase of mean survival time"/>
  <result pre="to publish the results. References References 1.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native" exact="influenza" post="virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 2.PflugA.GuilligayD.ReichS.CusackS.Structure of influenza A polymerase bound to"/>
  <result pre="References 1.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native influenza virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 2.PflugA.GuilligayD.ReichS.CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoterNature201451635536010.1038/nature1400825409142 3.NakatsuS.SagaraH.Sakai-TagawaY.SugayaN.NodaT.KawaokaY.Complete"/>
  <result pre="Packaging of Influenza A and B VirusesmBio2016710.1128/mBio.01248-1627601575 4.WeisW.BrownJ.H.CusackS.PaulsonJ.C.SkehelJ.J.WileyD.C.Structure of the" exact="influenza" post="virus haemagglutinin complexed with its receptor, sialic acidNature198833342643110.1038/333426a03374584 5.GamblinS.J.SkehelJ.J.Influenza"/>
  <result pre="5.GamblinS.J.SkehelJ.J.Influenza hemagglutinin and neuraminidase membrane glycoproteinsJ. Biol. Chem.2010285284032840910.1074/jbc.R110.12980920538598 6.BulloughP.A.HughsonF.M.SkehelJ.J.WileyD.C.Structure of" exact="influenza" post="haemagglutinin at the pH of membrane fusionNature1994371374310.1038/371037a08072525 7.PintoL.H.LambR.A.The M2"/>
  <result pre="the pH of membrane fusionNature1994371374310.1038/371037a08072525 7.PintoL.H.LambR.A.The M2 proton channels of" exact="influenza" post="A and B virusesJ. Biol. Chem.20062818997900010.1074/jbc.R50002020016407184 8.NeumannG.CastrucciM.R.KawaokaY.Nuclear import and"/>
  <result pre="and B virusesJ. Biol. Chem.20062818997900010.1074/jbc.R50002020016407184 8.NeumannG.CastrucciM.R.KawaokaY.Nuclear import and export of" exact="influenza" post="virus nucleoproteinJ. Virol.1997719690970010.1128/JVI.71.12.9690-9700.19979371635 9.AbrahamG.M.MortonJ.B.SaravolatzL.D.Baloxavir: A Novel Antiviral Agent in"/>
  <result pre="Treatment of InfluenzaClin. Infect. Dis.202010.1093/cid/ciaa107 10.De ClercqE.Antiviral agents active against" exact="influenza" post="A virusesNat. Rev. Drug Discov.200651015102510.1038/nrd217517139286 11.BragstadK.HungnesO.LitleskareI.NyrerodH.C.DorenbergD.H.HaugeS.H.Community spread and late"/>
  <result pre="Discov.200651015102510.1038/nrd217517139286 11.BragstadK.HungnesO.LitleskareI.NyrerodH.C.DorenbergD.H.HaugeS.H.Community spread and late season increased incidence of oseltamivir-resistant" exact="influenza" post="A(H1N1) viruses in Norway 2016Influenza Other Respir. Viruses20191337238110.1111/irv.1263730834715 12.PielakR.M.SchnellJ.R.ChouJ.J.Mechanism"/>
  <result pre="Respir. Viruses20191337238110.1111/irv.1263730834715 12.PielakR.M.SchnellJ.R.ChouJ.J.Mechanism of drug inhibition and drug resistance of" exact="influenza" post="A M2 channelProc. Natl. Acad. Sci. USA20091067379738410.1073/pnas.090254810619383794 13.HurtA.C.BesselaarT.G.DanielsR.S.ErmetalB.FryA.GubarevaL.HuangW.LackenbyA.LeeR.T.LoJ.et al.Global"/>
  <result pre="Sci. USA20091067379738410.1073/pnas.090254810619383794 13.HurtA.C.BesselaarT.G.DanielsR.S.ErmetalB.FryA.GubarevaL.HuangW.LackenbyA.LeeR.T.LoJ.et al.Global update on the susceptibility of human" exact="influenza" post="viruses to neuraminidase inhibitors, 2014-2015Antiviral Res.201613217818510.1016/j.antiviral.2016.06.00127265623 14.HurtA.C.ChotpitayasunondhT.CoxN.J.DanielsR.FryA.M.GubarevaL.V.HaydenF.G.HuiD.S.HungnesO.LackenbyA.et al.Antiviral resistance"/>
  <result pre="neuraminidase inhibitors, 2014-2015Antiviral Res.201613217818510.1016/j.antiviral.2016.06.00127265623 14.HurtA.C.ChotpitayasunondhT.CoxN.J.DanielsR.FryA.M.GubarevaL.V.HaydenF.G.HuiD.S.HungnesO.LackenbyA.et al.Antiviral resistance during the 2009" exact="influenza" post="A H1N1 pandemic: Public health, laboratory, and clinical perspectivesLancet"/>
  <result pre="Acidification and Viral Matrix Protein 2 FunctionJ. Virol.201892e01441-1810.1128/JVI.01441-1830282713 17.KimM.KimS.Y.LeeH.W.ShinJ.S.KimP.JungY.S.JeongH.S.HyunJ.K.LeeC.K.Inhibition of" exact="influenza" post="virus internalization by (-)-epigallocatechin-3-gallateAntiviral Res.201310046047210.1016/j.antiviral.2013.08.00223954192 18.NiemeyerG.CottierD.ReschH.Effects of buphenine (nylidrin)"/>
  <result pre="phosphateJ. Microbiol.20175597998310.1007/s12275-017-7371-x29214495 20.JangY.LeeH.W.ShinJ.S.GoY.Y.KimC.ShinD.MalpaniY.HanS.B.JungY.S.KimM.Antiviral activity of KR-23502 targeting nuclear export of" exact="influenza" post="B virus ribonucleoproteinsAntiviral Res.2016134778810.1016/j.antiviral.2016.07.02427565992 21.VinterJ.G.Extended electron distributions applied to"/>
  <result pre="some intermolecular interactionsJ. Comput Aided Mol Des.1994865366810.1007/BF001240137738602 22.VanderlindenE.GoktasF.CesurZ.FroeyenM.ReedM.L.RussellC.J.CesurN.NaesensL.Novel inhibitors of" exact="influenza" post="virus fusion: Structure-activity relationship and interaction with the viral"/>
  <result pre="to viral infectionJ. Exp. Med.202021710.1084/jem.20190554 29.MatsuiK.OzawaM.KisoM.YamashitaM.MaekawaT.KubotaM.SuganoS.KawaokaY.Stimulation of alpha2-adrenergic receptors impairs" exact="influenza" post="virus infectionSci. Rep.20188463110.1038/s41598-018-22927-029545586 30.LiT.W.ChengS.F.TsengY.T.YangY.C.LiuW.C.WangS.C.ChouM.J.LinY.J.WangY.HsiaoP.W.et al.Development of single-chain variable fragments"/>
  <result pre="infectionSci. Rep.20188463110.1038/s41598-018-22927-029545586 30.LiT.W.ChengS.F.TsengY.T.YangY.C.LiuW.C.WangS.C.ChouM.J.LinY.J.WangY.HsiaoP.W.et al.Development of single-chain variable fragments (scFv) against" exact="influenza" post="virus targeting hemagglutinin subunit 2 (HA2)Arch. Virol.2016161193110.1007/s00705-015-2625-626446888 31.GocnikM.FislovaT.SladkovaT.MuchaV.KostolanskyF.VareckovaE.Antibodies specific"/>
  <result pre="2 (HA2)Arch. Virol.2016161193110.1007/s00705-015-2625-626446888 31.GocnikM.FislovaT.SladkovaT.MuchaV.KostolanskyF.VareckovaE.Antibodies specific to the HA2 glycopolypeptide of" exact="influenza" post="A virus haemagglutinin with fusion-inhibition activity contribute to the"/>
  <result pre="against the fusion peptide of hemagglutinin protect mice from lethal" exact="influenza" post="A virus H5N1 infectionJ. Virol.2009832553256210.1128/JVI.02165-0819109379 33.BasuA.AntanasijevicA.WangM.LiB.MillsD.M.AmesJ.A.NashP.J.WilliamsJ.D.PeetN.P.MoirD.T.et al.New small molecule"/>
  <result pre="infectionJ. Virol.2009832553256210.1128/JVI.02165-0819109379 33.BasuA.AntanasijevicA.WangM.LiB.MillsD.M.AmesJ.A.NashP.J.WilliamsJ.D.PeetN.P.MoirD.T.et al.New small molecule entry inhibitors targeting hemagglutinin-mediated" exact="influenza" post="a virus fusionJ. Virol.2014881447146010.1128/JVI.01225-1324198411 34.WhiteK.M.De JesusP.ChenZ.AbreuP.Jr.BarileE.MakP.A.AndersonP.NguyenQ.T.InoueA.StertzS.et al.A Potent Anti-influenza"/>
  <result pre="hydrophobic; and yellow, van der Waals. Figure 2 Inhibition of" exact="influenza" post="virus infection by nylidrin. (A) Western blot analysis showing"/>
  <result pre="stained with DAPI. Original magnification, 630×. Figure 4 Inhibition of" exact="influenza" post="HA2-mediated membrane fusion by nylidrin. (A) Polykaryon formation assay."/>
  <result pre="5 In vivo antiviral activity of nylidrin against a mouse-adapted" exact="influenza" post="A virus (H1N1), maPR8. Before viral challenge, maPR8 (5"/>
  <result pre="1Table 1 Antiviral activity of nylidrin and its analogues against" exact="influenza" post="viruses, PR8, HK, and Lee. Compound CC50 (μM) a"/>
  <result pre="2 Antiviral activity of nylidrin and its analogues against various" exact="influenza" post="A and B viruses. Compound CC50 (μM) a to"/>
 </snippets>
</snippetsTree>
